Cellceutix announced more research data this morning on studies done with Kevetrin™, their leading compound for the treatment of specific stains of multi-drug resistant breast, lung and colon cancers. This series of testing was focused on Kevetrin affecting the life cycle of a specific lung cancer cell and was conducted by the Cellceutix research team at a major cancer hospital in Boston.
The data revealed that Kevetrin had a 78% effective rate of G2/M arrest and a 66% increase in apoptosis. To understand the significance of this data, it is important to know what portion of a cell’s life cycle this is targeting. The G2/M phase of the cycle is the area right before a cell enters mitosis, which is when the cell divides into two identical nuclei. It is clear that this is a critical time because treatments are designed by definition to stop the cells from further growth. Kevetrin demonstrated nearly 80% effectiveness with regards to the specific lung carcinoma cells in stopping the cell from entering the mitosis phase.
Apoptosis is defined as a specific form of programmed cell death without releasing harmful substances into the surrounding area. Kevetrin showed a great impact on the cancer cells with a 66% increase in apoptosis meaning that it is successfully killing the carcinoma cell without damaging the healthy cells around it. Efficient treatment of cancer cells is evolving into attacking the cells from multiple pathways rather than from simply one direction. The latest research demonstrates another pathway that Kevetrin is effective and coincides with previous studies that have shown other pathways that Kevetrin showed significant methods of action in slowing or stopping cancer cell growth.
Multi-drug resistant strains of cancers are becoming more prevalent in the world today. Cancer cells are very adept at modifying themselves to resist standard therapies. As this continues to be an issue in the cancer treatment industry, the need for new treatments continues to rise to combat these strains of cancer. Kevetrin is showing in pre-clinical studies that it could be a viable answer for this unmet need. Cellceutix is in late-stage pre-clinical trials and preparing for their IND filing for Kevetrin with the FDA. The filing is scheduled to be completed in the third quarter, which starts in ten days, with human trials targeted to commence in the fourth quarter of this year.
George Evans, CEO of Cellceutix, commented, “This data provides important insight into how Kevetrin is working to attack resistant cancer cells and significant because when dealing with drug-resistant cancers it is imperative to find multiple pathways to destroy the cells.” Mr. Evans continued, “We are very excited about the potential Kevetrin is presenting to the value of our company as all pre-clinical data has been extremely promising.”
More information on Cellceutix’s revolutionary compounds and the investment opportunity that they present can be found on the corporate website at www.cellceutix.com.
Let us hear your thoughts: Cellceutix Corp. Message Board